Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of plumbagin in preparation of medicine for preventing or treating Parkinson's disease

A technology for Parkinson's disease and plumbagin, which is applied in the field of new uses of plumbagin, can solve problems such as efficacy without any research, and achieve the effects of low toxicity, great new drug development value, and good application prospects.

Pending Publication Date: 2021-08-06
GUILIN MEDICAL UNIVERSITY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Plumbagin (Plumbagin, PL) is the main active ingredient of plumbagin, which has various pharmacological activities such as anti-inflammatory, anti-tumor, hypolipidemic, anti-malarial, antibacterial, neuroprotective, etc. Efficacy in Kinson's disease without any research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of plumbagin in preparation of medicine for preventing or treating Parkinson's disease
  • Application of plumbagin in preparation of medicine for preventing or treating Parkinson's disease
  • Application of plumbagin in preparation of medicine for preventing or treating Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0028] Study on plumbagin antagonizing MPP + Neurotoxic to PC12 cells and SH-SY5Y cells.

[0029] The experimental materials are: plumbagin (Sigma, USA), MPP + (Sigma, USA), rat adrenal pheochromocytoma cells PC12, SH-SY5Y cells, RPMI 1640 medium (Gibco), fetal bovine serum FBS (Gibco), horse serum (Gibco), Ham's F-12 , sodium pyruvate solution, MEM non-essential amino acid solution, glutamine additive, 100IU / ml penicillin-streptomycin mixture, Cell Counting Kit-8 (Dongren Chemical Technology (Shanghai) Co., Ltd.).

[0030] The experimental groups are: the experiment is set as the normal control group (A), MPP + Exposure group (B), plumbagin low-dose protection group (C), plumbagin medium-dose protection group (D), plumbagin high-dose protection group (E), plumbagin low-dose control group (F) , plumbagin middle-dose control group (G), plumbagin high-dose control group (H). Wherein the control group (A) does not give administration, gives normal saline, MPP + The exposure ...

experiment example 2

[0037] To investigate the effect of plumbacean on neuronal death and motor dysfunction in MPTP-induced subacute and chronic parkinsonian mice.

[0038] The experimental materials are: plumbaceous quinone (Sigma, USA), MPTP (Sigma, USA), TH monoclonal antibody (EMD Millipore), fluorescent secondary antibody (Jackson ImmunoResearch Laboratories), goat serum stock solution (Beijing Zhongshan Jinqiao Biotechnology Co., Ltd. ), rotating rod fatigue tester (Shanghai Xinruan Information Technology Co., Ltd.), open field test box (Shanghai Xinruan Information Technology Co., Ltd.), cryostat (Germany Leica Company), upright fluorescence microscope (Olympus Corporation ).

[0039] Experimental animals and grouping: adult male 3-month-old C57BL / 6 mice were randomly divided into 4 groups, 15 mice in each group, respectively normal control group, MPTP exposure group, plumbagin protection group, plumbagin control group . Among them, the control group was given normal saline, the MPTP expo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of new application of plumbagin, and provides application of plumbagin in preparation of a medicine for preventing or treating Parkinson's disease. The toxic effect of neurotoxin MPP + / MPTP on Parkinson's disease and the toxic effect of plumbagin on antagonism of MPP <+> / MPTP on Parkinson's disease are observed through cell and animal experiments. Researches show that plumbagin can inhibit SH-SY5Y and PC12 nerve cells and dopaminergic neuron death and dyskinesia caused by neurotoxin MPP <+> / MPTP. Therefore, the plumbagin has good application prospects and huge new medicine development value in the aspects of Parkinson's disease prevention and treatment and neuroprotection.

Description

technical field [0001] The invention relates to the technical field of new applications of plumbagin, in particular to the application of plumbagin in the preparation of drugs for preventing or treating Parkinson's disease. Background technique [0002] Parkinson's disease (PD) is a progressive neurodegenerative disease commonly seen in the elderly. The prevalence rate of people over 65 years old in my country is about 1.7%. Its main clinical symptoms are resting tremor, muscle Rigidity, bradykinesia, and abnormal gait, non-motor symptoms manifest as sleep disturbance, constipation, depression, hyposmia, etc. The main pathological features of this disease are the loss of dopaminergic neurons in the substantia nigra pars compacta and the formation of Lewy bodies mainly composed of α-synuclein. The pathogenesis of Parkinson's disease is complex and closely related to mitochondrial dysfunction, oxidative stress, abnormal aggregation of α-synuclein, neuroinflammation, autophagy ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/122A61K36/185A61P25/16
CPCA61K31/122A61K36/185A61P25/16
Inventor 闫建国周亚莉苏燕方方乔冠华何玉林徐兴凤李茂
Owner GUILIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com